KR20180011331A - Lsd1 억제제와 관련된 바이오마커 및 그의 용도 - Google Patents

Lsd1 억제제와 관련된 바이오마커 및 그의 용도 Download PDF

Info

Publication number
KR20180011331A
KR20180011331A KR1020187001221A KR20187001221A KR20180011331A KR 20180011331 A KR20180011331 A KR 20180011331A KR 1020187001221 A KR1020187001221 A KR 1020187001221A KR 20187001221 A KR20187001221 A KR 20187001221A KR 20180011331 A KR20180011331 A KR 20180011331A
Authority
KR
South Korea
Prior art keywords
trans
patient
disease
inhibitor
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187001221A
Other languages
English (en)
Korean (ko)
Inventor
타마라 마에스
크리스티나 마스카로 크루사트
다비드 르트얀 포소
Original Assignee
오리존 지노믹스 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리존 지노믹스 에스.에이. filed Critical 오리존 지노믹스 에스.에이.
Publication of KR20180011331A publication Critical patent/KR20180011331A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187001221A 2015-06-12 2016-06-10 Lsd1 억제제와 관련된 바이오마커 및 그의 용도 Withdrawn KR20180011331A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15382310 2015-06-12
EP15382310.9 2015-06-12
EP15382369.5 2015-07-17
EP15382369 2015-07-17
PCT/EP2016/063368 WO2016198649A1 (en) 2015-06-12 2016-06-10 Biomarkers associated with lsd1 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20180011331A true KR20180011331A (ko) 2018-01-31

Family

ID=56345081

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187001221A Withdrawn KR20180011331A (ko) 2015-06-12 2016-06-10 Lsd1 억제제와 관련된 바이오마커 및 그의 용도
KR1020187001123A Expired - Fee Related KR102372194B1 (ko) 2015-06-12 2017-06-09 Lsd1 억제제를 이용한 다발성 경화증의 치료방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187001123A Expired - Fee Related KR102372194B1 (ko) 2015-06-12 2017-06-09 Lsd1 억제제를 이용한 다발성 경화증의 치료방법

Country Status (22)

Country Link
US (1) US20180284095A1 (enExample)
EP (1) EP3307909A1 (enExample)
JP (3) JP6855466B2 (enExample)
KR (2) KR20180011331A (enExample)
CN (2) CN107849611A (enExample)
AU (2) AU2016275702A1 (enExample)
BR (1) BR112018075310A2 (enExample)
CA (1) CA2987876A1 (enExample)
CY (1) CY1121988T1 (enExample)
DK (1) DK3307267T3 (enExample)
HR (1) HRP20191121T1 (enExample)
HU (1) HUE043954T2 (enExample)
IL (2) IL256208A (enExample)
LT (1) LT3307267T (enExample)
MX (2) MX2017015922A (enExample)
MY (1) MY190849A (enExample)
PT (1) PT3307267T (enExample)
RU (1) RU2768120C2 (enExample)
SG (1) SG10201911989SA (enExample)
SM (1) SMT201900353T1 (enExample)
TR (1) TR201909353T4 (enExample)
WO (2) WO2016198649A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021125732A1 (ko) * 2019-12-19 2021-06-24 재단법인 대구경북과학기술원 콧물 시료를 이용한 경도 인지 장애의 진단용 바이오마커 조성물 및 이를 이용한 경도 인지 장애의 진단 방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
AU2016275702A1 (en) * 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
US11013698B2 (en) 2016-03-15 2021-05-25 Oryzon Genomics S.A. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
PL3307267T3 (pl) 2016-06-10 2019-10-31 Oryzon Genomics Sa Leczenie stwardnienia rozsianego
JP2019128317A (ja) * 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の診断マーカー又は診断キット
US20210228490A1 (en) * 2018-05-04 2021-07-29 Oryzon Genomics, S.A. Stable pharmaceutical formulation

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0833901A1 (en) * 1995-06-07 1998-04-08 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
EP1193261A1 (en) * 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
KR20080088570A (ko) 2005-08-10 2008-10-02 더 존스 홉킨스 유니버시티 항기생충 및 항암 치료제 및 라이신-특이적인 디메틸라제억제제로 유용한 폴리아민
EP2142287A4 (en) 2007-04-13 2012-05-23 Univ Johns Hopkins INHIBITORS OF LYSINPECIFIC DEMETHYLASE
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010111712A2 (en) * 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2258865A1 (en) * 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
WO2010143582A1 (ja) 2009-06-11 2010-12-16 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びlsd1阻害剤
US9708255B2 (en) 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
AU2011244478B2 (en) 2010-04-20 2014-07-17 Fondazione IEO-CCM Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
SI2598482T1 (sl) * 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba
US9527805B2 (en) 2010-09-10 2016-12-27 Robert A. Casero Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
CA2831143C (en) 2011-03-25 2019-05-21 Glaxosmithkline Intellectual Property Development Limited Cyclopropylamines as lsd1 inhibitors
UA114406C2 (uk) 2011-08-09 2017-06-12 Такеда Фармасьютікал Компані Лімітед Похідні циклопропанаміну як інгібітори lsd1
SG2014009609A (en) 2011-08-15 2014-05-29 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
US9751885B2 (en) 2012-10-12 2017-09-05 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
EP2927212A4 (en) 2012-11-28 2016-06-08 Univ Kyoto LSD1-SELECTIVE HEMMER WITH LYSINE STRUCTURE
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
US9918983B2 (en) 2013-05-30 2018-03-20 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
KR102288648B1 (ko) 2013-06-19 2021-08-12 유니버시티 오브 유타 리서치 파운데이션 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
AU2014306149B2 (en) 2013-08-06 2019-09-19 Imago Biosciences Inc. KDM1A inhibitors for the treatment of disease
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
PL3080100T3 (pl) 2013-12-11 2023-03-06 Celgene Quanticel Research, Inc. Inhibitory lizyno-specyficznej demetylazy-1
US10118903B2 (en) 2014-02-07 2018-11-06 Musc Foundation For Research Development Aminotriazole-based KDM1A inhibitors as epigenetic modulators
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
SG11201608340UA (en) 2014-04-11 2016-11-29 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
HUE057895T2 (hu) 2014-05-01 2022-06-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibitorai
AU2015265820C1 (en) 2014-05-30 2020-01-16 Ieo - Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine compounds as histone demethylase inhibitors
MX376632B (es) 2014-06-27 2025-03-07 Celgene Quanticel Res Inc Inhibidores de demetilasa-1 especifica de lisina.
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
EA033698B1 (ru) 2014-07-03 2019-11-18 Celgene Quanticel Res Inc Ингибиторы лизинспецифической деметилазы-1
MX391865B (es) 2014-07-03 2025-03-21 Celgene Quanticel Res Inc Inhibidores de demetilasa-1 especifica de lisina.
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
AU2016275702A1 (en) * 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021125732A1 (ko) * 2019-12-19 2021-06-24 재단법인 대구경북과학기술원 콧물 시료를 이용한 경도 인지 장애의 진단용 바이오마커 조성물 및 이를 이용한 경도 인지 장애의 진단 방법

Also Published As

Publication number Publication date
MY190849A (en) 2022-05-12
JP2018522581A (ja) 2018-08-16
AU2016275702A1 (en) 2017-12-21
IL256207A (en) 2018-02-28
BR112018075310A2 (pt) 2019-03-19
AU2017277751A1 (en) 2018-02-01
HK1253743A1 (en) 2019-06-28
JP2019023202A (ja) 2019-02-14
HUE043954T2 (hu) 2019-09-30
IL256207B (en) 2022-05-01
KR102372194B1 (ko) 2022-03-08
LT3307267T (lt) 2019-07-25
US20180284095A1 (en) 2018-10-04
KR20190016478A (ko) 2019-02-18
AU2017277751B2 (en) 2018-03-01
RU2019100037A3 (enExample) 2020-07-13
JP2018534234A (ja) 2018-11-22
PT3307267T (pt) 2019-07-04
CA2987876A1 (en) 2016-12-15
EP3307909A1 (en) 2018-04-18
MX2017015922A (es) 2018-12-11
RU2019100037A (ru) 2020-07-13
IL256208A (en) 2018-02-28
CY1121988T1 (el) 2020-10-14
CN107921029B (zh) 2021-09-28
SG10201911989SA (en) 2020-02-27
SMT201900353T1 (it) 2019-07-11
WO2017212061A1 (en) 2017-12-14
CN107921029A (zh) 2018-04-17
TR201909353T4 (tr) 2019-07-22
CN107849611A (zh) 2018-03-27
WO2016198649A1 (en) 2016-12-15
DK3307267T3 (da) 2019-07-01
HRP20191121T1 (hr) 2019-09-20
NZ738830A (en) 2018-12-21
JP6411680B1 (ja) 2018-10-24
RU2768120C2 (ru) 2022-03-23
MX2017015921A (es) 2018-12-11
JP6855466B2 (ja) 2021-04-07

Similar Documents

Publication Publication Date Title
JP6855466B2 (ja) Ｌｓｄ１阻害剤に関連するバイオマーカーおよびそれらの使用
WO2017013061A1 (en) Biomarkers associated with lsd1 inhibitors and uses thereof
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
JP6240063B2 (ja) ヒストンデアセチラーゼ阻害剤
CN103124724B (zh) Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
JP4775259B2 (ja) アニリン誘導体
CA2915622C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
TWI690318B (zh) 作爲ｂａｃｅ１抑制劑之２-胺基-６-（二氟甲基）-５,５-二氟-６-苯基-３,４,５,６-四氫吡啶
CN111225903B (zh) 谷氨酰胺酶抑制剂疗法
US20190062284A1 (en) Small molecule inhibitors of dyrk1a and uses thereof
JP2022508751A (ja) Ｐｆｋｆｂ３阻害剤とその使用
US12195783B2 (en) Methods to determine KDM1A target engagement and chemoprobes useful therefor
WO2018133795A1 (zh) 一种ezh2抑制剂及其用途
EP3911317A2 (en) Methods of treating cartilage disorders through inhibition of clk and dyrk
JP2020143087A (ja) 障害を治療するための５ｈｔ作動薬
US20060217404A1 (en) Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases
CN101855203A (zh) F1f0-atp合成酶抑制剂以及相关的方法
CN101801362A (zh) 用于治疗病症的方法和组合物
US20220280484A1 (en) Novel use
US10758522B2 (en) Small molecule analogs of the nemo binding peptide
JP2020537122A (ja) 老化細胞のためのバイオマーカー
CN110035749A (zh) Fabp4作为皮肤病中的治疗靶
JPWO2016063990A1 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
CN106536500A (zh) 选择性基质金属蛋白酶抑制剂
Fan et al. Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination